On Wednesday, Vor Bio Inc. announced that its collaborator, RemeGen Co., Ltd., achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in adults with IgA nephropathy (IgAN).

IgA nephropathy, also known as Berger’s disease, is an autoimmune kidney disease where abnormal clumps of the antibody immunoglobulin A (IgA) deposit in the kidneys’ filtering units, the glomeruli, causing inflammation and damage.

Details of the study results will be presented at an upcoming medical conference.

Also Read: Vor Biopharma’s RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

“Telitacicept continues to demonstrate consistent, disease-modifying activity across autoimmune conditions, from myasthenia gravis to Sjögren’s disease and now IgA nephropathy,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board.

The study in China enrolled 318 adult IgAN patients who had received standard therapy.

In Stage A of the Phase 3 study, telitacicept achieved the primary endpoint of reducing proteinuria, demonstrating a 55% reduction in 24-hour urine protein-to-creatinine ratio (UPCR) at 39 weeks compared with placebo (p